Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2024

Commission File Number: 001-41641

SHL TELEMEDICINE LTD.

(Translation of registrant’s name into English)

90 Yigal Alon Street

Tel Aviv 67891, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

On December 10, 2024, SHL Telemedicine Ltd. (the “Company”) announced that at the Special General Meeting of Shareholders of the Company held on December 10, 2024 (the “Meeting”), the sole proposal to elect Orna Carni as an external director of the Company, to serve for a term of three years commencing at the Meeting or until her office is vacated in accordance with the Company’s Articles of Association or the Israel Companies Law, 5759-1999, was approved by the shareholders. A copy of the press release issued by the Company on December 10, 2024, and announcing the election of Ms. Carni is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

This Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 9, 2023 (Registration No. 333-272546), and its Registration Statement on Form 20FR12B/A filed with the Securities and Exchange Commission on March 28, 2023 (File No. 001-41641).

Exhibit

Description

99.1	Press release, dated December 10, 2024, announcing the results of the Special General Meeting of Shareholders.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SHL Telemedicine Ltd.

	By:	/s/ Amir Hai
		Amir Hai
		Chief Financial Officer

December 10, 2024

Exhibit 99.1

Press release

SHL announces Special General Meeting Results

Tel Aviv / Zurich / New York, December 10, 2024 – SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN) (“SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, announced today that at the Special General Meeting (“SGM”) of the Shareholders that was held today in Tel-Aviv, Israel, the Company’s shareholders approved the following resolution:

•	To approve the election of Orna Carni as an external director of the Company, to serve for a term of three years commencing at the SGM date or until her office is vacated in accordance with the Company’s Articles of Association or the Israel Companies Law, 5759-1999.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200).

For more information, please visit our web site at www.shl-telemedicine.com.

Contacts

Fabienne Farner, IRF, Phone: +41 43 244 81 42, farner@irf-reputation.ch

Forward-Looking Statements

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.

SHL Telemedicine (NASDAQ:SHLT)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025